Vascular cell adhesion and migration, proliferation or differentiation are cellular responses that are induced by haemostatic factors of the urokinase/plasminogen activation complex, but the respective underlying mechanisms are largely undefined. The direct and indirect contributions of the urokinase-type plasminogen activator receptor (uPAR) system in inflammatory processes, as they relate to recruitment of leukocytes, define novel functions and could serve as therapeutic targets for related vasculopathies. The presence of uPAR plays a crucial role in &integrin-mediated adhesion of leukocytes; uPAR also directly mediates leukocyte adhesion to vitronectin, a multifunctional adhesion protein that is associated with the extracellular matrix. The latter process is inhibited by plasminogen activator inhibitor-1 .
Introduction
Cell adhesion, migration and invasion depend on the co-ordinated expression and function of various adhesion receptors, such as integrins, together with the pericellular activities of protease systems that counteract cell-substratum and cell-cell interactions. The plasminogen activation system, which includes the urokinase-type plasminogen activator (uPA), tissue-type plasminogen activators, their inhibitors, plasminogen, and their respective cell-surface-binding proteins/receptors plays a central role in cell invasion [l]. Moreover, evidence of a crosstalk between components of the plasminogen activation system with adhesion receptors, extracellular matrix (ECM) proteins and signalling molecules, processes that are partially independent of the proteolytic activity, has provided new insights into the role of this system as a co-ordinator of cell adhesion [2] .
Direct role of uPA receptor (uPAR) in cell adhesion: regulation by Zn2+, plasminogen-activator inhibitor-I (PAL I) and high-molecular-mass kininogen (HK)
Specific evidence has emerged in recent years that the uPAR acts in cell adhesion both directly, as a cell-linked adhesion protein or counter-receptor, or indirectly, as a modulator of integrins in association with additional cytoskeleton and signalling proteins [3, 4] . A member of the family of Ly-6-related factors, uPAR is a highly glycosylated 55-60 kDa protein [5, 6] that consists of three homologous domains and that is anchored to the plasma membrane by a glycosylphosphatidylinositol (GPI) moiety that is susceptible to hydrolysis by GPI-specific phospholipases. The GPI-anchor gives uPAR a relatively high lateral mobility in the plasma membrane, and like other GPI-anchored proteins, uPAR tends to concentrate in lipid rafts (glycosphingolipid-and cholesterol-rich membrane microdomains) that exhibit a lower fluidity than the surrounding plasma membrane and thereby enable the assembly of multireceptor adhesion complexes and signalling molecules within these ' signalosomes ' [7, 8] . In some epithelial cell types, uPAR also localizes to plasma membrane invaginations, caveolae, which contain signalling centres together with the cholesterol-binding scaffolding protein caveolin [9] . uPAR is expressed on the surface of many cell types including circulating blood leukocytes, endothelial and vascular smooth muscle cells, fibroblasts and bone marrow cells, as well as a variety of neoplastic cells [1, 5] , and its expression level on cells strongly correlates with their migratory and invasive potential [lo] and with poor prognosis in different types of tumours [ll] , although proteolytic activity is not always required.
Three unrelated extracellular protein ligands have been identified for uPAR: uPA, vitronectin (VN), and two-chain kinin-free high-molecularmass kininogen (HKa) [4, 12] . In addition, certain integrin a-chains may interact directly with uPAR in a cis-or trans-type manner [13]. In particular, intact uPAR binds with high affinity via multidomain interactions to the N-terminal portion of (pro-)uPA [14], thereby focusing proteolytic activity at the cell surface, especially at the leading edge of migrating cells [15] . VN causes uPAR to act as an adhesion receptor for leukocytic cells, whereby uPA increases uPAR's affinity for VN and enhances the adhesiveness of these cells to immobilized VN [16] . Interestingly, Zn2+ was also shown to increase the affinity of the uPAR-VN interaction, whereas other divalent cations had no such effect. As a consequence, physiological concentrations of Zn2+ could upregulate uPARmediated monocyte adhesion to VN [ 171. As the binding sites for both uPAR and PAI-1 are located in close proximity to the N-terminal portion of VN (the 'somatomedin B domain'), PAI-1 can prevent VN from binding to the uPAR, thereby acting as a potent anti-adhesive factor [18, 19] . These activities of uPA and PAI-1 are independent of any proteolytic or anti-proteolytic activity, and may contribute to pathophysiological processes in angiogenesis or atherosclerosis.
The third uPAR ligand, HKa, which lacks the proteolytically released vasodilator peptide bradykinin, binds to uPAR in a Zn-dependent manner [12] . Initially identified as a non-enzymic cofactor in the initiation of the contact phase [20] , H K appears to be associated with vascular injury, inflammation or the activation of complement in humoral immune defence. Kallikrein can liberate the short-lived vasodilator peptide bradykinin from H K [20], thereby generating HKa, which that competes with VN for binding to uPAR and dissociates cell-bound VN from uPAR, thereby serving as another anti-adhesive factor in an ECM-selective fashion [21] . These effects are predominantly attributed to domain 5 of HK.
Moreover, HK/HKa binding to cells contributes to the regulation of pericellular plasmin generation by modulating plasma kallikrein-dependent formation of uPA, a reaction that is dependent on the binding of plasma prekallikrein to H K domain 6 [22] . Limited proteolysis of uPAR between domains 1 and 2 by extended exposure to uPA (or other proteases) in vitro and in vivo generates a truncated two-domain form, which lacks binding capacity for VN and uPA, but still presents unaltered binding to HKa [21] . We recently showed that HKa, and domain 5 in particular, binds directly to the N-terminus of VN. Owing to the close proximity or overlap of binding sites for uPAR, PAI-1, HKa and a,-integrins along the N-terminal portion of VN, a very similar inhibition of uPAR-dependent leukocyte adhesion, as well as integrin-dependent endothelial cell adhesion to VN by PAI-1 and HKa, was observed [21, 23] . Furthermore, HKa can displace PAI-1 from ECM-bound VN in vitro and thereby potentially competes with PAI-1 's anti-fibrinolytic activity. These reactions are in accordance with the observation that kininogen-free animals have a prothrombotic phenotype following arterial injury [24, 25] . Furthermore, results from different murine models of (tumour) angiogenesis indicate that upon gene inactivation of PAI-1, neovascularization in the tumour tissue is significantly impaired [26] . These results are consistent with the proposed anti-adhesive role of PAI-1 in cellular interactions.
Owing to the GPI-anchor of uPAR, the cellular contacts formed directly between uPARbearing cells and VN-rich substratum are different from typical cytoskeleton-associated (clustered) adhesion receptors, which can resist mechanical stress. Oligomerization of uPAR and the uPARuPA complex might ensure at least a temporary mechanical stability for direct uPAR-mediated cell adhesion to VN. Indeed, we could observe that such uPAR-uPAR cis-interactions on the cell 
Regulation of integrin-dependent adhesion phenomena by uPAR and HK
In addition to this direct role in cell adhesion, it has been suggested that uPAR affects cell adhesion indirectly by regulating integrin affinity and activation [3, 4] . It has also been observed that both HK and HKa interact specifically with Mac-1 but not with LFA-1, thereby blocking Mac-1 -dependent leukocyte adhesion to fibrinogen and to endothelial cells in vitro and interfering with neutrophil migration during acute inflammation in vivo [39] .
This effect of kininogen was attributed to domain 5, and specifically to the sequence which is located in the C-terminal portion of this domain. T h e described anti-inflammatory properties of HK are independent of uPAR, and they define H K as a major player in controlling the cell adhesion balance by preventing excessive leukocyte recruitment and hyperinflammatory responses. Furthermore, these mechanisms are in agreement with the first description of a patient with H K (' Fitzgerald factor') deficiency, in whom excessive leukocyte migration was observed using a skin window device [40, 41] . The characterized peptide sequences in domain 5 of H K that are involved in inhibition of Mac-1 function can provide new therapeutic substances to inhibit leukocyte infiltration in patients. Surprisingly, this region overlaps with the H K sequence ( L y~~* ' -T h r~'~) , which was recently described to induce endothelial cell apoptosis and to inhibit angiogenesis [42] . Thus, the C-terminus of domain 5 of H K provides important features which could serve as endogenous regulatory elements during wound healing, inflammation or angiogenesis. Further studies will demonstrate whether this internal peptide can be used as lead substance for novel low-molecular-mass drugs to be used for therapeutic interventions in hyperinflammatory or malignant situations in patients (Figure 1 ).
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Regulation of monocyte adhesion in acute myocardial infarction (AMI) by uPAR
Leukocyte recruitment is fundamental for the development of atherosclerosis or restenosis following percutaneous coronary interventions, as well as for myocardial damage after ischaemia and reperfusion [43, 44] . Our recent results demonstrate that in AMI, changes in the level of uPAR on monocytes can alter integrin-dependent and integrin-independent cell adhesion. In particular, uPAR surface expression on human monocytes was upregulated in the peripheral blood of patients with AMI. The functional relevance of these changes in uPAR expression for cell adhesion was shown with respect to its function both as an adhesion receptor and as a co-receptor for integrins. Enhanced uPAR expression on monocytes from patients with AM1 was associated with increased cell adhesion to the uPAR ligand VN and with enhanced cell adhesion to the Mac-1 ligands fibrinogen and ICAM-1 on the endothelium. In contrast with uPAR upregulation on monocytes, no changes in quantitative Mac-1 surface expression were observed, however, elevated uPAR expression resulted in enhanced activation of P,-integrins. Thus, our results suggest that increased availability of uPAR in AM1 may prime monocytes for enhanced adhesive responsiveness to additional inflammatory stimuli. T h e development of specific antagonists against the uPAR system for prevention of detrimental monocytic cell recruitment during cardiovascular inflammatory processes might prove beneficial This mitogenic effect of uPA was independent of its ability to activate plasminogen and to bind to the described uPAR. Although anti-uPAR antibodies were effective in inhibiting the binding of uPA to vascular smooth muscle cells, as was the phosphatidylinositol-specific phospholipase C-mediated removal of the glycolipid-anchored uPAR, neither of these treatments inhibited the growth-stimulatory activity of (pro-)uPA. An attractive possibility that needs further experimental validation is that the effect of uPA is transduced independently of the classic uPAR and through another uPA-binding protein. Preliminary experiments provide evidence for novel, cellsurface-located uPA-binding proteins on vascular smooth muscle cells. Moreover, uPA can interact with ECM proteins and bind to lipoprotein receptor-related protein in the presence of PAI-1 [46] . These results are in accordance with those generated in transgenic mice deficient in individual components of the fibrinolytic system. While tissue-type plasminogen activator or uPAR de-ficiency did not influence the formation of a neointima following vascular injury, uPA deficiency substantially reduced neointimal cell accumulation [47] . In addition, uPA, but not uPAR, seems to be involved in processes leading to atherosclerotic aneurysm formation and myocardial rupture [48] . These results, together with the well described effect of uPA on smooth muscle cell migration and its role in remodelling of the ECM, provide additional evidence for the involvement of uPA in vasoproliferative disorders.
Perspectives
Based on the discussed behaviour of the uPAR system in inflammatory processes in vitro and in vivo, novel insights into the underlying molecular mechanisms are expected, and promising strategies for therapeutic interventions in hyperinflammatory situations, atherosclerosis or tumour metastasis can be expected. In particular, ongoing research indicates that uPAR-dependent p,-integrin-mediated cell adhesion and aggregation also occurs under flow or shear stress, and several signalling pathways appear to be involved. T h e co-localization of uPAR with several other signalling receptors and adaptor proteins within cholesterol/sphingolipid-rich lipid rafts on the cell surface has implications for the control of uPAR-dependent interactions. T h e disturbance of such 'signalosomes' by lipid lowering drugs would thereby directly translate into antiinflammatory consequences during therapy with, for example statins, a situation which has been proven already by experiments in vitro (T. Chavakis, unpublished work) . Moreover, the use of natural anti-inflammatory substances such as kininogen-based fragments could be extended for the prevention of the serious outcome of atherosclerosis or of restenosis, or to prevent the extravasation of circulating tumour cells and thereby interfere with tumour metastasis at its earliest phase. Our results provide the potential for new tools for several therapeutic interventions in inflammation-based vasculopathies.
Introduction
Trousseau was the first to observe frequent blood coagulation in cancer patients [l] . Since then many investigators have provided evidence supporting the view that systemic activation of the blood clotting cascade is evident in patients with cancer [2] . For example, high levels of circulating fibrinopeptides are present in patients with cancer, which
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